SCHEMBL29642984

SCHEMBL29642984

CC(C)(C)OC(=O)Nc1cccc(C[C@H](N)c2nccs2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.45
RPS6KB1 P23443 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.42
METAP1 P53582 1/20 0.41
CYP17A1 P05093 2/20 0.40
HDAC3 O15379 4/20 0.39
HDAC1 Q13547 4/20 0.39
HDAC2 Q92769 4/20 0.39
HDAC10 Q969S8 4/20 0.39
HDAC8 Q9BY41 3/20 0.39
SLC7A5 Q01650 1/20 0.39
SREBF2 Q12772 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
GLS O94925 1/20 0.38
HDAC6 Q9UBN7 3/20 0.38
PTPRB P23467 1/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28531300 1.00 AURKA (0.45) AURKARPS6KB1SIRT2METAP1CYP17A1
SCHEMBL23682527 1.00 AURKA (0.45) AURKARPS6KB1SIRT2METAP1CYP17A1
SCHEMBL28524920 0.90 AURKA (0.44) AURKARPS6KB1SIRT2METAP1CYP17A1
SCHEMBL29643010 0.90 AURKA (0.44) AURKARPS6KB1SIRT2METAP1CYP17A1
SCHEMBL21598776 0.84 NOS3 (0.43) AURKASIRT2PTPRBNOS3NOS1
SCHEMBL21598775 0.84 NOS3 (0.43) AURKASIRT2PTPRBNOS3NOS1
SCHEMBL29642978 0.83 METAP1 (0.40) AURKARPS6KB1SIRT2METAP1CYP17A1
SCHEMBL28531299 0.78 CTSA (0.39) PTPRB
SCHEMBL2367233 0.77 SLC7A5 (0.64) AURKARPS6KB1CYP17A1SLC7A5NOS3
SCHEMBL16856591 0.77 AURKA (0.47) AURKARPS6KB1SIRT2CYP17A1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240352122-A1 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF NOVARTIS AG (CH) 2024-10-24 US disclosed
US-11999786-B2 Anti-CD48 antibodies, antibody drug conjugates, and uses thereof NOVARTIS AG (CH) 2024-06-04 US disclosed
EP-4251648-A2 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF Novartis AG (CH) 2023-10-04 EP disclosed
WO-2022112942-A2 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF NOVARTIS AG (CH) 2022-06-02 WO disclosed
US-20220162308-A1 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF NOVARTIS AG (CH) 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999786-B2 Anti-CD48 antibodies, antibody drug conjugates, and uses thereof ITGB8, ITGA8, CD4 AURKA 1956/4885RPS6KB1 3097/4885SIRT2 4455/4885
US-20240352122-A1 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF ITGB8, ITGA8, CD4 AURKA 1956/4885RPS6KB1 3097/4885SIRT2 4455/4885
US-20220162308-A1 ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF ITGB8, ITGA8, CD4 AURKA 1956/4885RPS6KB1 3097/4885SIRT2 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.